At 8.3% CAGR, North America PCR Technologies Market is Projected to be Worth US$ 9,634.86 Million by 2030, says Business Market Insights

According to Business Market Insights research, the North America PCR technologies market was valued at US$ 5,075.81 million in 2022 and is expected to reach US$ 9,634.86 million by 2030, registering a CAGR of 8.3% from 2022 to 2030. Rising prevalence of genetic and infectious diseases and surging investments and funds availability for PCR technologies are among the critical factors attributed to the North America PCR technologies market expansion.

According to the National Organization's information on genetic conditions or congenital disabilities, genetic disorders are rare conditions, but they collectively comprise over 15,500 positive diagnoses every year. Estimates published in a report by MJH Life Sciences (US) in 2022 state that ~300,000 newborns are born with sickle cell disease (SCD) globally every year, accounting for ~5% of the global population. Further, as per the June 2020 report by Novartis AG, SCD affects around eight million individuals globally. In the US, SCD is one of the most prevalent genetic conditions. According to the Centers for Disease Control and Prevention (CDC), 1 in 500 African Americans is affected by an SCD, and 1 in 12 of them suffer from the autosomal recessive mutation. As a result of the rising incidence of SCDs, the adoption of digital polymerase chain reaction (dPCR) is increasing in pathology centers, wherein this technology is being exploited for targeting various DNA-specific sequences to confirm diagnoses and design various clinical tests. dPCR can target specific DNA sequences in just one molecule of DNA. This tool allows researchers to detect rare genetic mutations that are difficult to identify by using real-time PCR. The COVID-19 outbreak had a significant impact on the PCR technologies market. PCR is a nearly ubiquitous, robust, and reliable technology used in most molecular biology labs to amplify specific stretches of DNA for genotyping, cloning, and analysis of single nucleotide variations. The amplified DNA even serves as the basis for most next-generation sequencing (NGS) preparation. Nearly all diagnostic tests used real-time PCR for testing people having symptoms of COVID-19. Most of the biotech and pharmaceutical businesses shifted their focus toward research and development (R&D) divisions to find novel compounds or therapeutic approaches for COVID-19, which, in turn, benefitted the PCR technologies market. In February 2022, Roche added the Cobas 5800 System, a newly released molecular laboratory instrument, to its COVID-19 PCR portfolio for use in nations that accept the CE certification. These products include the Cobas SARS-CoV-2 and influenza A/B tests, as well as the Cobas SARS-CoV-2 qualitative test. The product offers uniform performance and efficiency in low-, medium-, and high-volume molecular laboratory tests. Thus, the increasing incidence of genetic and infectious diseases supports the growth of the PCR technologies market.

On the contrary, high costs of PCR systems and availability of alternative assay hampers the growth of North America PCR technologies market.

Based on technology, the North America PCR technologies market is segmented into real time PCR, conventional PCR, reverse transcription, digital PCR, multiplex RTPCR, hot start PCR, and others. The real time PCR segment held 38.1% share of North America PCR technologies market in 2022, amassing US$ 1,931.76 million. It is projected to garner US$ 3,867.59 million by 2030 to expand at 9.1% CAGR during 2022-2030.

In terms of offerings, the North America PCR technologies market is segmented into reagents & consumables, instruments, and software & services. The reagents & consumables segment held 58.1% share of North America PCR technologies market in 2022, amassing US$ 2,949.24 million. It is projected to garner US$ 6,000.39 million by 2030 to expand at 9.3% CAGR during 2022-2030. Further, reagents & consumables segment are categorized into reagents, vials size, and other consumables. Furthermore, vials size is segmented into 0.2ml to 2ml, 0.1 ml to 0.3 ml, 2 ml to 5ml, and other vials. Additionally, instruments segment is bifurcated into benchtop PCR and portable thermocyclers/PCR.

By application, the North America PCR technologies market is segmented into gene expression analysis, genetic sequencing, genotyping, nucleic acid synthesis, standard validation, point of care diagnostic application, environmental application, and others. The gene expression analysis segment held 22.9% share of North America PCR technologies market in 2022, amassing US$ 1,163.50 million. It is projected to garner US$ 2,362.96 million by 2030 to expand at 9.3% CAGR during 2022-2030.

Based on end user, the North America PCR technologies market is segmented into hospitals & diagnostic centers, pharmaceutical & biotechnology companies, academic institutes & research laboratories, and others. The hospitals & diagnostic centers segment held 56.2% share of North America PCR technologies market in 2022, amassing US$ 2,851.84 million. It is projected to garner US$ 5,629.55 million by 2030 to expand at 8.9% CAGR during 2022-2030.

By country, the North America PCR technologies market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 83.4% share of North America PCR technologies market in 2022. It was assessed at US$ 4,233.23 million in 2022 and is likely to hit US$ 8,116.95 million by 2030, exhibiting a CAGR of 8.5% during 2022-2030.

Key players operating in the North America PCR technologies market are Thermo Fisher Scientific Inc, Promega Corp, QIAGEN NV, bioMerieux SA, Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, Becton Dickinson and Co, Atila Biosystems Inc, Takara Bio Inc, Standard Bio Tools Inc, Agilent Technologies Inc, Visby Medical Inc, and Ellume Ltd, among others.

• In November 2023, Qiagen launched new kits for use on its QIAcuity systems and a major new software update designed to expand the portfolio of applications for use of digital PCR technology in areas like cell and gene therapies, DNA and RNA quantification, as well as food and pharmaceuticals safety.
  
  
• In February 2021, Thermo Fisher Scientific Inc announced the complete acquisition of Mesa Biotech Inc, a point-of-care molecular diagnostic company. The acquisition has allowed Thermo Fisher Scientific Inc to expand its portfolio with a point-of-care PCR-based testing platform for infectious disease diagnosis. And since 2021, Mesa Biotech Inc has become a part of the Life Sciences Solution Segment.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com